FDA approves Pfizer's rheumatoid arthritis treatment

Share this article:
FDA approves Pfizer's rheumatoid arthritis treatment
FDA approves Pfizer's rheumatoid arthritis treatment
Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually. Xeljanz is taken in 5-milligram pills twice daily.  About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wound healing.
Share this article:

More in Products

Last day to enter McKnight's Tech Awards

Today is the final day to submit entries into the third annual McKnight's Excellence in Technology Awards.

AliMed offers three new fall management products

AliMed offers three new fall management products

AliMed is now offering the AliMed CordLess® Sensor Alarm and the AliMed Worry-Free Fall Alarm to help reduce the risk of accidental falls, and the HipShield® X-tra to help prevent ...

Diamond Wipes creates new wipes

Diamond Wipes creates new wipes

Diamond Wipes has announced an updated version of its Handyclean™ cleaning and sanitizing wipes.